TY  - CONF
AU  - Perez Villardon, B
AU  - Garcia Bellon, AM
AU  - Jimenez Rubio, C
AU  - Rubio Alcaide, A
AU  - Perez Benito, L
AU  - Ramirez Marrero, MA
AU  - De Mora Martin, M
AU  - De Teresa Galvan, E
PY  - 2016
SN  - 0390-6078
UR  - http://hdl.handle.net/10668/2439
T2  - Haematologica
AB  - Atrial fibrillation (AF) is the most common arrhythmia. It leads to significant morbidity and mortality. The new oral anticoagulants (NOAC) represent an improvement compared with standard treatment (vitamin K antagonists(AVK)) in the prevention of...
LA  - en
PB  - Ferrata Storti Foundation
KW  - Anticoagulantes
KW  - Fibrilación atrial
KW  - Fibrinolíticos
KW  - Humanos
KW  - Vitamina K
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants
KW  - Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Arrhythmias, Cardiac::Atrial Fibrillation
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Fibrinolytic Agents
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Polycyclic Hydrocarbons, Aromatic::Naphthalenes::Naphthoquinones::Vitamin K
TI  - Oral direct anticoagulants in the treatment of nonvalvular atrial fibrillation. Results of the daily clinical practice.
TY  - conference presentation
ER  -